DISCOUNT-ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 07:45:31 2024-06-14 am EDT | ||
| 37.51 EUR | +0.67% |
|
| Current month | +2.53% | ||
| 1 month | -6.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 37.51 | +0.67% |
| 24-06-13 | 37.26 | -1.53% |
| 24-06-12 | 37.84 | -1.46% |
| 24-06-11 | 38.4 | +0.87% |
| 24-06-10 | 38.07 | +3.14% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 07:45 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC8REC |
| ISIN | DE000HC8REC3 |
| Date issued | 2023-08-16 |
| Maturity | 2024-12-20 (189 Days) |
| Parity | 1 : 1 |
| Emission price | 42.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 43.96 € |
|---|---|
| Lowest since issue | 35.58 € |
| Spread | 0.02 € |
| Spread % | 0.05% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Certificates
- Certificat
